Sexual Coercion in Breast Cancer Patients Treated With Luteinizing Hormone-Releasing Hormone Agonists (LHRHa )

NCT ID: NCT06840847

Last Updated: 2025-02-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 79 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-01-01
• Study Completion Date: 2024-10-29

Brief Summary

The use of luteinizing hormone-releasing hormone agonists(LHRHa) to suppress ovarian function is a common strategy for treating premenopausal, hormone receptor-positive breast cancer. However, this approach can lead to more severe and prolonged menopausal symptoms, which can further impact intimate relationships and sexual function. Sexual coercion, encompassing both overt and subtle forms of pressure, is a significant global public health concern that threatens individual well-being.

Detailed Description

Objective: The use of luteinizing hormone-releasing hormone agonists(LHRHa) to suppress ovarian function is a common strategy for treating premenopausal, hormone receptor-positive breast cancer. However, this approach can lead to more severe and prolonged menopausal symptoms, which can further impact intimate relationships and sexual function. Sexual coercion, encompassing both overt and subtle forms of pressure, is a significant global public health concern that threatens individual well-being.

Methods: This study is a randomized controlled study. In this study, the validated Turkish version of the Sexual Coercion in Intimate Relationship Scale was utilized to investigate whether patients receiving LHRHa therapy experienced higher rates of sexual sexual coercion compared to those taking tamoxifen. The study included 40 patients using LHRHa and 39 patients using tamoxifen. The instrument assessed partner sexual coercion across three subdomains: resource manipulation/sexual coercion, commitment manipulation, and defection threat.

Conditions

Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: FACTORIAL
• Primary Study Purpose: HEALTH_SERVICES_RESEARCH
• Blinding Strategy: NONE

Study Groups

LHRHa

In this study, included 40 patients on LHRHa. The instrument assessed partner sexual coercion in three domains: resource manipulation/sexual coercion, commitment manipulation, and threat of separation.

Group Type: ACTIVE_COMPARATOR

Sexual Coercion

Intervention Type: BEHAVIORAL

This study aimed to investigate whether patients receiving LHRHa treatment experienced sexual coercion at a higher rate than those using tamoxifen. 40 patients using LHRHa and 39 patients using tamoxifen were included in the study.

Tamoxifen (Nolvadex)

In this study included 39 patients on tamoxifen. The instrument assessed partner sexual coercion in three domains: resource manipulation/sexual coercion, commitment manipulation, and threat of separation.

Group Type: ACTIVE_COMPARATOR

Sexual Coercion

Intervention Type: BEHAVIORAL

This study aimed to investigate whether patients receiving LHRHa treatment experienced sexual coercion at a higher rate than those using tamoxifen. 40 patients using LHRHa and 39 patients using tamoxifen were included in the study.

Interventions

Sexual Coercion

This study aimed to investigate whether patients receiving LHRHa treatment experienced sexual coercion at a higher rate than those using tamoxifen. 40 patients using LHRHa and 39 patients using tamoxifen were included in the study.

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• being over 18 years of age
• willingness to participate in this study
• having received treatment for breast cancer
• having a history of breast cancer surgery
• having an active relationship with a spouse or partner.

Exclusion Criteria

• having any neuropsychiatric disorder
• having any mental illness
• having a history of gynecological surgery
• currently receiving active chemotherapy or less than 3 months since completing chemotherapy
• receiving treatment for metastatic disease
• The use of selective serotonin reuptake inhibitors

• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Canan Kas

OTHER

Sponsor Role: lead

Responsible Party

Canan Kas

PhD, MSc, RN, Assistant Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

Kastamonu University

Kastamonu, Merkez, Turkey (Türkiye)

Countries

Turkey (Türkiye)

Other Identifiers

Kastamonu Universty 2023/148

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

2023-KAEK-148

Identifier Type: -

Identifier Source: org_study_id